XenoPort Inc. (Nasdaq: XNPT) reported positive results from a Phase 2
clinical trial of its psoriasis treatment XP23829 but the stock price tumbled $1.89 to close at $4.84.
XenoPort reports positive trial data
September 15, 2015 at 11:42 AM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.